{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:44:06Z","timestamp":1792122246697,"version":"4.4.0"},"reference-count":251,"publisher":"Elsevier","isbn-type":[{"value":"9780128118016","type":"print"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/bs.aivir.2016.07.001","type":"book-chapter","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T01:46:51Z","timestamp":1470188811000},"page":"187-243","source":"Crossref","is-referenced-by-count":315,"title":["Modified Vaccinia Virus Ankara"],"prefix":"10.1016","author":[{"given":"A.","family":"Volz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.aivir.2016.07.001_bb0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0092-8674(92)90274-G","article-title":"A soluble receptor for interleukin-1\u03b2 encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection","volume":"71","author":"Alcami","year":"1992","journal-title":"Cell"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0147-9571(96)00013-6","article-title":"Soluble interferon-\u03b3 receptors encoded by poxviruses","volume":"19","author":"Alcam\u00ed","year":"1996","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.4049\/jimmunol.160.2.624","article-title":"Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus","volume":"160","author":"Alcam\u00ed","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0020","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0025","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.4049\/jimmunol.172.5.3094","article-title":"Enhanced CD8+ T cell immune responses and protection elicited against plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus","volume":"172","author":"Anderson","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0378-1119(96)00267-3","article-title":"Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes","volume":"24","author":"Antoine","year":"1996","journal-title":"Gene"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0040","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1099\/vir.0.015347-0","volume":"91","author":"Backes","year":"2010","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0045","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1371\/journal.ppat.0040005","article-title":"Structure and function of A41, a vaccinia virus chemokine binding protein","volume":"4","author":"Bahar","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0050","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire Ebola virus disease in guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0055","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1128\/jvi.66.8.4710-4719.1992","article-title":"Mutational analysis of the core, spacer, and initiator regions of vaccinia virus intermediate-class promoters","volume":"66","author":"Baldick","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0060","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cell.2014.10.046","article-title":"Accelerating HIV-1 vaccine efficacy trials","volume":"159","author":"Barouch","year":"2014","journal-title":"Cell"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0065","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrmicro3360","article-title":"Novel vaccine vectors for HIV-1","volume":"12","author":"Barouch","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0070","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.pctr.0010029","article-title":"A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"1","author":"Bejon","year":"2006","journal-title":"PLoS Clin. Trials"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0075","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1128\/jvi.70.9.6418-6424.1996","article-title":"Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza","volume":"70","author":"Bender","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8(+) T-cell immunogenicity in humans of a novel heterosubtypic influenza a vaccine, MVA\u2212NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0085","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.0401939101","article-title":"Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice","volume":"101","author":"Bisht","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0090","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/322373a0","article-title":"Oral vaccination of the fox against rabies using a live recombinant vaccinia virus","volume":"322","author":"Blancou","year":"1986","journal-title":"Nature"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0378-1119(95)00149-Z","article-title":"Selection of recombinant vaccinia viruses on the basis of plaque formation","volume":"158","author":"Blasco","year":"1995","journal-title":"Gene"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0105","doi-asserted-by":"crossref","first-page":"29946","DOI":"10.1074\/jbc.M004077200","article-title":"Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-IR) family: delineation of a new class of IL-1R-related proteins based on signaling","volume":"275","author":"Born","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0110","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1083\/jcb.106.3.761","article-title":"Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line","volume":"106","author":"Boukamp","year":"1988","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.meegid.2012.12.002","article-title":"A survey of host range genes in poxvirus genomes","volume":"14","author":"Bratke","year":"2013","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0120","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.vaccine.2005.08.091","article-title":"Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge","volume":"24","author":"Breathnach","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0125","unstructured":"Bundesamt f\u00fcr Vebraucherschutz und Lebensmittelsicherheit, 2002. Stellungnahme der ZKBS zur Risikobewertung des rekombinanten Vacciniavirus MVA. Az. 6790-10-74."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/viro.2000.0689","article-title":"Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities","volume":"279","author":"Calderara","year":"2001","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0135","first-page":"352","article-title":"E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses","volume":"19","author":"Carroll","year":"1995","journal-title":"Biotechniques"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0145","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1128\/MCB.5.12.3403","article-title":"Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques","volume":"5","author":"Chakrabarti","year":"1985","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0150","doi-asserted-by":"crossref","first-page":"ofw034","DOI":"10.1093\/ofid\/ofw034","article-title":"Strong, but age-dependent, protection elicited by a deoxyribonucleic acid\/modified vaccinia Ankara simian immunodeficiency virus vaccine","volume":"3","author":"Chamcha","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0155","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1073\/pnas.89.11.4825","article-title":"The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase","volume":"89","author":"Chang","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0160","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1177\/0300985810378649","article-title":"Animal models of orthopoxvirus infection","volume":"47","author":"Chapman","year":"2010","journal-title":"Vet. Pathol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0165","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/JVI.79.5.2678-2688.2005","article-title":"Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region","volume":"79","author":"Chen","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0170","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40259-013-0046-1","article-title":"Emerging targets and novel approaches to Ebola virus prophylaxis and treatment","volume":"27","author":"Choi","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1099\/vir.0.81417-0","article-title":"Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy","volume":"87","author":"Clark","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0180","doi-asserted-by":"crossref","first-page":"e1638","DOI":"10.1371\/journal.pone.0001638","article-title":"Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)","volume":"3","author":"Cottingham","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","article-title":"The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection","volume":"341","author":"Coulibaly","year":"2005","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0190","doi-asserted-by":"crossref","first-page":"e1003989","DOI":"10.1371\/journal.ppat.1003989","article-title":"Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS\/STING-mediated cytosolic DNA-sensing pathway","volume":"10","author":"Dai","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0195","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/jvi.66.4.1943-1950.1992","article-title":"The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2","volume":"66","author":"Davies","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0200","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0022-2836(89)90108-3","article-title":"Structure of vaccinia virus late promoters","volume":"210","author":"Davison","year":"1989","journal-title":"J. Mol. Biol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0205","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/39218","article-title":"A pandemic warning?","volume":"389","author":"de Jong","year":"1997","journal-title":"Nature"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0210","doi-asserted-by":"crossref","first-page":"e1005221","DOI":"10.1371\/journal.ppat.1005221","article-title":"Ebolavirus evolution: past and present","volume":"11","author":"de La Vega","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0215","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3201\/eid2106.150021","article-title":"Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine","volume":"21","author":"De Vries","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0220","doi-asserted-by":"crossref","first-page":"e1000480","DOI":"10.1371\/journal.ppat.1000480","article-title":"Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome","volume":"5","author":"Delaloye","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0225","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1099\/vir.0.057299-0","article-title":"New vaccinia virus promoter as a potential candidate for future vaccines","volume":"94","author":"Di Pilato","year":"2013","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0230","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1099\/vir.0.000183","article-title":"Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression","volume":"96","author":"Di Pilato","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0235","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1099\/jgv.0.000266","article-title":"Redundancy complicates the definition of essential genes for vaccinia virus","volume":"96","author":"Dobson","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0240","doi-asserted-by":"crossref","first-page":"12415","DOI":"10.1073\/pnas.192420599","article-title":"Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells","volume":"99","author":"Domi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nmeth734","article-title":"Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage [lambda]-based recombination","volume":"2","author":"Domi","year":"2005","journal-title":"Nat. Methods"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0250","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cell.2006.02.005","article-title":"The rational design of an AIDS vaccine","volume":"124","author":"Douek","year":"2006","journal-title":"Cell"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0255","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79","author":"Drexler","year":"1998","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0260","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1073\/pnas.262668999","article-title":"Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines","volume":"100","author":"Drexler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0265","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1128\/jvi.28.3.843-850.1978","article-title":"Host range restriction of vaccinia virus in Chinese hamster ovary cells: relationship to shutoff of protein synthesis","volume":"28","author":"Drillien","year":"1978","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0270","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0042-6822(81)90351-2","article-title":"Host range deletion mutant of vaccinia virus defective in human cells","volume":"111","author":"Drillien","year":"1981","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0275","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1006\/viro.2001.1345","article-title":"Comparison of vaccine strategies using recombinant env\u2013gag\u2013pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model","volume":"294","author":"Earl","year":"2002","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0280","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0285","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0290","series-title":"Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines","author":"EMA","year":"2010"},{"issue":"1","key":"10.1016\/bs.aivir.2016.07.001_bb0295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00125682","article-title":"Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies","volume":"1","author":"Esposito","year":"1987","journal-title":"Virus Genes"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0300","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1099\/vir.0.81090-0","article-title":"Ectromelia virus: the causative agent of mousepox","volume":"86","author":"Esteban","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0305","series-title":"Imvanex: Modifiziertes Vacciniavirus Ankara Lebend","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0310","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0315","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0320","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.4161\/hv.28462","article-title":"HIV-1 vaccines","volume":"10","author":"Excler","year":"2014","journal-title":"Hum. Vac. Immunother."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0325","doi-asserted-by":"crossref","first-page":"e32220","DOI":"10.1371\/journal.pone.0032220","article-title":"Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein","volume":"7","author":"Falivene","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0330","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/jvi.62.6.1849-1854.1988","article-title":"Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors","volume":"62","author":"Falkner","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0335","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1099\/vir.0.054114-0","article-title":"Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence","volume":"94","author":"Ferguson","year":"2013","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0340","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/vim.2011.0018","article-title":"Recombinant MVA expressing secreted glycoprotein D of BoHV-1 induces systemic and mucosal immunity in animal models","volume":"24","author":"Ferrer","year":"2011","journal-title":"Viral Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0345","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.cdd.4401718","article-title":"Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis","volume":"13","author":"Fischer","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0350","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature11858","article-title":"H5N1 virus: transmission studies resume for avian flu","volume":"493","author":"Fouchier","year":"2013","journal-title":"Nature"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0355","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2015.06.075","article-title":"Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na\u00efve subjects","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0360","doi-asserted-by":"crossref","first-page":"e5445","DOI":"10.1371\/journal.pone.0005445","article-title":"Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategies","volume":"4","author":"Garber","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0365","doi-asserted-by":"crossref","first-page":"e24244","DOI":"10.1371\/journal.pone.0024244","article-title":"A candidate HIV\/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses","volume":"6","author":"Garc\u00eda-Arriaza","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0370","doi-asserted-by":"crossref","first-page":"e66894","DOI":"10.1371\/journal.pone.0066894","article-title":"Improving adaptive and memory immune responses of an HIV\/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways","volume":"8","author":"Garc\u00eda-Arriaza","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0375","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1128\/JVI.02723-13","article-title":"Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens","volume":"88","author":"Garc\u00eda-Arriaza","year":"2014","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/bs.aivir.2016.07.001_bb9000","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/biot.201400388","article-title":"Designing cell lines for viral vaccine production: where do we stand?","volume":"10","author":"Genzel","year":"2015","journal-title":"Biotechnol. J."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0380","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nbt1197-1280","article-title":"A protein particle vaccine containing multiple malaria epitopes","volume":"15","author":"Gilbert","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0385","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0264-410X(01)00450-9","article-title":"Enhanced CD8T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime\u2013boost immunisation regimes","volume":"20","author":"Gilbert","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0390","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1073\/pnas.83.15.5573","article-title":"Localization and sequence of a vaccinia virus gene required for multiplication in human cells","volume":"83","author":"Gillard","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0395","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1126\/science.1259657","article-title":"Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak","volume":"345","author":"Gire","year":"2014","journal-title":"Science"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0400","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0042-6822(90)90294-2","article-title":"The complete DNA sequence of vaccinia virus","volume":"179","author":"Goebel","year":"1990","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0405","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/infdis\/jiu003","article-title":"Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"210","author":"Goepfert","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0410","first-page":"89","article-title":"West Nile fever; the clinical features of the disease and the isolation of West Nile virus from the blood of nine human cases","volume":"59","author":"Goldblum","year":"1954","journal-title":"Am. J. Hyg."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0415","doi-asserted-by":"crossref","first-page":"e35485","DOI":"10.1371\/journal.pone.0035485","article-title":"Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV\/AIDS of clade C","volume":"7","author":"G\u00f3mez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0420","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.74.1919.371","article-title":"The cultivation of vaccine and other viruses in the chorioallantoic membrane of chick embryos","volume":"74","author":"Goodpasture","year":"1931","journal-title":"Science"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0425","first-page":"271","article-title":"Vaccinal infection of the chorio-allantoic membrane of the chick embryo","volume":"8","author":"Goodpasture","year":"1932","journal-title":"Am. J. Pathol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0430","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.171.3.1602","article-title":"Enhanced immunogenicity and protective efficacy against mycobacterium tuberculosis of bacille calmette-gu\u00e9rin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara","volume":"171","author":"Goonetilleke","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0435","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/viro.1996.8423","article-title":"The T1\/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues","volume":"229","author":"Graham","year":"1997","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0440","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrmicro3143","article-title":"A decade after SARS: strategies for controlling emerging coronaviruses","volume":"11","author":"Graham","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0445","doi-asserted-by":"crossref","first-page":"e0138348","DOI":"10.1371\/journal.pone.0138348","article-title":"A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18\u201340 year old subjects with diagnosed atopic dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0450","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1473-3099(13)70690-X","article-title":"Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation","volume":"14","author":"Haagmans","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"6268","key":"10.1016\/bs.aivir.2016.07.001_bb0455","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.aad1283","article-title":"An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels","volume":"351","author":"Haagmans","year":"2016","journal-title":"Science"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0460","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.meegid.2013.10.014","article-title":"Poxviruses and the evolution of host range and virulence","volume":"21","author":"Haller","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0465","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1099\/0022-1317-79-1-83","article-title":"Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice","volume":"79","author":"Hanke","year":"1998","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0470","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.4049\/jimmunol.173.6.4050","article-title":"Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines","volume":"173","author":"He","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0475","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/v7020709","article-title":"Poxviral ankyrin proteins","volume":"7","author":"Herbert","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0480","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza a\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0485","first-page":"479","article-title":"Comparative experimental works on cow pox virus vaccines","volume":"138","author":"Herrlich","year":"1954","journal-title":"Arch. Hyg. Bakteriol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0490","doi-asserted-by":"crossref","first-page":"e12217","DOI":"10.1371\/journal.pone.0012217","article-title":"A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations","volume":"5","author":"Hessel","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0495","doi-asserted-by":"crossref","first-page":"e16247","DOI":"10.1371\/journal.pone.0016247","article-title":"Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity","volume":"6","author":"Hessel","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.aivir.2016.07.001_bb9005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.virol.2007.11.034","article-title":"Characterization of wild-type and mutant vaccinia virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-kappaB activation during infection","volume":"373","author":"Hinthong","year":"2008","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0500","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/jvi.70.6.3741-3752.1996","article-title":"Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara","volume":"70","author":"Hirsch","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0505","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1016\/j.amepre.2015.09.011","article-title":"The march toward malaria vaccines","volume":"49","author":"Hoffman","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0510","doi-asserted-by":"crossref","first-page":"8394","DOI":"10.1128\/JVI.77.15.8394-8407.2003","article-title":"Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L","volume":"77","author":"Hornemann","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0515","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/0042-6822(90)90367-Z","article-title":"Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses","volume":"178","author":"Isaacs","year":"1990","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0520","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ni1282","article-title":"A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA","volume":"7","author":"Ishii","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0525","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/vaccines2010160","article-title":"DNA\/MVA vaccines for HIV\/AIDS","volume":"2","author":"Iyer","year":"2014","journal-title":"Vaccines"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0530","doi-asserted-by":"crossref","first-page":"994","DOI":"10.4049\/jimmunol.1500083","article-title":"Codelivery of envelope protein in alum with MVA vaccine induces CXCR3-biased CXCR5+ and CXCR5\u2212 CD4T cell responses in rhesus macaques","volume":"195","author":"Iyer","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0535","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.0405954101","article-title":"Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox","volume":"101","author":"Jahrling","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0540","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3201\/eid2111.151016","article-title":"Middle east respiratory syndrome in 3 persons, South Korea, 2015","volume":"21","author":"Jeong-Sun","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0545","doi-asserted-by":"crossref","first-page":"e0118486","DOI":"10.1371\/journal.pone.0118486","article-title":"Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults","volume":"10","author":"Joachim","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/bs.aivir.2016.07.001_bb0550","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/CVI.00216-16","article-title":"MVA vaccination provides long-term protection against nasal rabbitpox virus challenge","volume":"23","author":"Jones","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0555","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biologicals.2010.11.005","article-title":"A chemically defined production process for highly attenuated poxviruses","volume":"39","author":"Jordan","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0560","doi-asserted-by":"crossref","first-page":"13300","DOI":"10.1128\/JVI.01532-14","article-title":"Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene","volume":"88","author":"Kamlangdee","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0565","doi-asserted-by":"crossref","first-page":"11193","DOI":"10.1038\/srep11193","article-title":"Comparative assessment of transmission-blocking vaccine candidates against plasmodium falciparum","volume":"5","author":"Kapulu","year":"2015","journal-title":"Sci. Rep."},{"issue":"5990","key":"10.1016\/bs.aivir.2016.07.001_bb0570","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/312163a0","article-title":"Expression of rabies virus glycoprotein from a recombinant vaccinia virus","volume":"312","author":"Kieny","year":"1984","journal-title":"Nature"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0575","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3947\/ic.2015.47.4.278","article-title":"Middle east respiratory syndrome infection control and prevention guideline for healthcare facilities","volume":"47","author":"Kim","year":"2015","journal-title":"Infect. Chemother."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0580","doi-asserted-by":"crossref","first-page":"e114374","DOI":"10.1371\/journal.pone.0114374","article-title":"Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection","volume":"9","author":"Knitlova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0585","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/517614","article-title":"Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1","volume":"195","author":"Kreijtz","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0590","doi-asserted-by":"crossref","first-page":"e7790","DOI":"10.1371\/journal.pone.0007790","article-title":"MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza a\/H5N1 viruses at low doses and after single immunization","volume":"4","author":"Kreijtz","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0595","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1086\/595984","article-title":"Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques","volume":"199","author":"Kreijtz","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0600","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1099\/vir.0.024885-0","article-title":"Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A\/H1N1 vaccine in the ferret model","volume":"91","author":"Kreijtz","year":"2010","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0605","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza a H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0610","doi-asserted-by":"crossref","first-page":"e1002557","DOI":"10.1371\/journal.ppat.1002557","article-title":"Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox","volume":"8","author":"Kremer","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0615","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-61779-876-4_4","article-title":"Easy and efficient protocols for working with recombinant vaccinia virus MVA","volume":"890","author":"Kremer","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0620","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2011.08.018","article-title":"Zoonotic Brazilian vaccinia virus: from field to therapy","volume":"92","author":"Kroon","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0625","series-title":"Hot Topics in Infection and Immunity in Children VIII","first-page":"59","article-title":"Pigs, poultry, and pandemic influenza: how zoonotic pathogens threaten human health","author":"Kuiken","year":"2011"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0630","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1128\/JVI.03527-14","article-title":"CD40L-adjuvanted DNA\/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection","volume":"89","author":"Kwa","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0635","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/srep01443","article-title":"Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1","volume":"3","author":"Lambe","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0640","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1126\/science.286.5448.2333","article-title":"Origin of the west Nile virus responsible for an outbreak of encephalitis in the northeastern united states","volume":"286","author":"Lanciotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0645","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/JVI.01884-08","article-title":"Modified vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression","volume":"83","author":"Lehmann","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0650","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0655","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1128\/JVI.02262-14","article-title":"SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0660","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.vaccine.2009.05.083","article-title":"New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation","volume":"27","author":"Lohr","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0665","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcv.2016.04.005","article-title":"Factors associated with poor outcomes among adults hospitalized for influenza in France: a three-year prospective multicenter study","volume":"79","author":"Loubet","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0670","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1128\/JVI.79.4.2584-2596.2005","article-title":"Role of viral factor E3L in modified vaccinia virus Ankara infection of human HeLa cells: regulation of the virus life cycle and identification of differentially expressed host genes","volume":"79","author":"Ludwig","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0675","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1099\/vir.0.81623-0","article-title":"Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara","volume":"87","author":"Ludwig","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0680","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.79.23.7415","article-title":"Vaccinia virus: a selectable eukaryotic cloning and expression vector","volume":"79","author":"Mackett","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0685","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1128\/jvi.49.3.857-864.1984","article-title":"General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes","volume":"49","author":"Mackett","year":"1984","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0690","first-page":"253","article-title":"Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA","volume":"107","author":"Mahnel","year":"1994","journal-title":"Berl. Munch. Tierarztl. Wochenschr."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0695","first-page":"24","article-title":"Ver\u00e4nderung von Vaccinevirus durch Dauerpassagen in H\u00fchnerembryofibroblastenkulturen","volume":"195","author":"Mayr","year":"1964","journal-title":"Zentralbl. Bakteriol. B"},{"issue":"8","key":"10.1016\/bs.aivir.2016.07.001_bb0700","first-page":"580","article-title":"Experimental research on the S-antigen in the viruses of animal smallpox","volume":"139","author":"Mayr","year":"1955","journal-title":"Arch. Hyg. Bakteriol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0705","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Abstammung, Eigenschaften und Verwendung des attenuierten vaccinia-Stammes MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0710","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/cid\/cit703","article-title":"Human monkeypox","volume":"58","author":"McCollum","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0715","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrmicro1099","article-title":"Poxvirus tropism","volume":"3","author":"McFadden","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0720","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tube.2013.11.003","article-title":"A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data","volume":"94","author":"McShane","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0725","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1128\/IAI.70.3.1623-1626.2002","article-title":"Protective immunity against mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8+- and CD4+-T-cell epitopes from antigen 85A","volume":"70","author":"McShane","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0730","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0735","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3201\/eid2006.140402","article-title":"Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013","volume":"20","author":"Memish","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0740","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11262-005-1784-z","article-title":"F-box-like domains are present in most poxvirus Ankyrin repeat proteins","volume":"31","author":"Mercer","year":"2005","journal-title":"Virus Genes"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0745","doi-asserted-by":"crossref","first-page":"e0149364","DOI":"10.1371\/journal.pone.0149364","article-title":"Percutaneous vaccination as an effective method of delivery of MVA and MVA-vectored vaccines","volume":"11","author":"Meseda","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0750","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0755","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3201\/eid2004.131746","article-title":"Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013","volume":"20","author":"Meyer","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0760","doi-asserted-by":"crossref","first-page":"25359","DOI":"10.1038\/srep25359","article-title":"Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity","volume":"6","author":"Min","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0765","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1086\/378515","article-title":"Safety and immunogenicity of DNA\/modified vaccinia virus Ankara malaria vaccination in African adults","volume":"188","author":"Moorthy","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0770","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(03)15267-1","article-title":"Malaria vaccine developments","volume":"363","author":"Moorthy","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0775","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1110\/ps.03554604","article-title":"The Ankyrin repeat as molecular architecture for protein recognition","volume":"13","author":"Mosavi","year":"2004","journal-title":"Protein Sci."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0780","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","article-title":"Smallpox vaccines: targets of protective immunity","volume":"239","author":"Moss","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0785","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/eji.201242922","article-title":"Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine","volume":"43","author":"Mullarkey","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0790","doi-asserted-by":"crossref","first-page":"e0119629","DOI":"10.1371\/journal.pone.0119629","article-title":"Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial","volume":"10","author":"Munseri","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0795","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1051\/vetres\/2010039","article-title":"West Nile virus and its emergence in the United States of America","volume":"41","author":"Murray","year":"2010","journal-title":"Vet. Res."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0800","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1073\/pnas.79.5.1593","article-title":"Molecular genetics of vaccinia virus: demonstration of marker rescue","volume":"79","author":"Nakano","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0805","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJM200106143442401","article-title":"The outbreak of West Nile virus infection in the New York City area in 1999","volume":"344","author":"Nash","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0810","first-page":"221","article-title":"Equine vaccine for West Nile virus","volume":"114","author":"Ng","year":"2003","journal-title":"Dev. Biol. (Basel)"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0815","doi-asserted-by":"crossref","first-page":"e0131748","DOI":"10.1371\/journal.pone.0131748","article-title":"HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy swedish HIV-1 DNA\/MVA vaccinees: a phase I randomized trial","volume":"10","author":"Nilsson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0820","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/viro.2001.1090","article-title":"Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kB activation","volume":"288","author":"Oie","year":"2001","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0825","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3389\/fmicb.2014.00439","article-title":"The influence of delivery vectors on HIV vaccine efficacy","volume":"5","author":"Ondondo","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0830","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/mt.2016.3","article-title":"Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection","volume":"24","author":"Ondondo","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0835","doi-asserted-by":"crossref","first-page":"ofv040","DOI":"10.1093\/ofid\/ofv040","article-title":"Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial","volume":"2","author":"Overton","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0840","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1073\/pnas.79.16.4927","article-title":"Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus","volume":"79","author":"Panicali","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0845","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1086\/595565","article-title":"Postexposure immunization with modified vaccinia virus Ankara or conventional lister vaccine provides solid protection in a murine model of human smallpox","volume":"199","author":"Paran","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0850","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2008.11.015","article-title":"Mousepox in the C57BL\/6 strain provides an improved model for evaluating anti-poxvirus therapies","volume":"385","author":"Parker","year":"2009","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0855","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0042-6822(90)90296-4","article-title":"Vaccinia virus host range genes","volume":"179","author":"Perkus","year":"1990","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0860","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/sj.cdd.4401853","article-title":"Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis","volume":"13","author":"Postigo","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0865","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1473-3099(15)00361-8","article-title":"Ebola: lessons learned and future challenges for Europe","volume":"16","author":"Quaglio","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0870","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0875","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3201\/eid2008.140663","article-title":"Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014","volume":"20","author":"Raj","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0880","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/514544a","article-title":"Forgotten\u2019 NIH smallpox virus languishes on death row","volume":"514","author":"Reardon","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0885","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coviro.2016.01.004","article-title":"Cross host transmission in the emergence of MERS coronavirus","volume":"16","author":"Reusken","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0890","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/1743-422X-8-529","article-title":"Selection of recombinant MVA by rescue of the essential D4R gene","volume":"8","author":"Ricci","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0895","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1084\/jem.54.4.453","article-title":"Cultivation of vaccine virus for Jennerian prophylaxis in man","volume":"54","author":"Rivers","year":"1931","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0900","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1084\/jem.58.5.635","article-title":"Further observations on the cultivation of vaccine virus for Jennerian prophylaxis in man","volume":"58","author":"Rivers","year":"1933","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0905","doi-asserted-by":"crossref","first-page":"e34445","DOI":"10.1371\/journal.pone.0034445","article-title":"Vaccine efficacy against malaria by the combination of Porcine Parvovirus-Like particles and vaccinia virus vectors expressing cs of plasmodium","volume":"7","author":"Rodr\u00edguez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0910","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature12893","article-title":"Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV","volume":"505","author":"Roederer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0915","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.1222526","article-title":"The potential for respiratory droplet-transmissible A\/H5N1 influenza virus to evolve in a mammalian host","volume":"336","author":"Russell","year":"2012","journal-title":"Science"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0920","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2144\/000112012","article-title":"Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker","volume":"39","author":"S\u00e1nchez-Puig","year":"2005","journal-title":"Biotechniques"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0925","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00103-015-2168-8","article-title":"Lessons learnt from the German smallpox outbreaks after World War II","volume":"58","author":"Sasse","year":"2015","journal-title":"Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0930","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nm0498-397","article-title":"Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara","volume":"4","author":"Schneider","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0935","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/14760584.2016.1106319","article-title":"Recombinant modified vaccinia virus Ankara-based malaria vaccines","volume":"15","author":"Sebastian","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0940","doi-asserted-by":"crossref","first-page":"e0141687","DOI":"10.1371\/journal.pone.0141687","article-title":"A Phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults","volume":"10","author":"Sheehan","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/bs.aivir.2016.07.001_bb9010","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1128\/JVI.78.7.3553-3560.2004","article-title":"The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation","volume":"78","author":"Shisler","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0945","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/bs.ai.2015.10.001","article-title":"Chapter six\u2014the pathogenesis and immunobiology of mousepox","author":"Sigal","year":"2016"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0950","doi-asserted-by":"crossref","first-page":"e01122","DOI":"10.1128\/mBio.01122-15","article-title":"Identification of restriction factors by human genome-wide RNA interference screening of viral host range mutants exemplified by discovery of SAMd9 and WDR6 as inhibitors of the vaccinia virus K1L(\u2212)C7L(\u2212) mutant","volume":"6","author":"Sivan","year":"2015","journal-title":"mBio"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0955","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1099\/0022-1317-81-5-1223","article-title":"Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins","volume":"81","author":"Smith","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0960","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1074\/jbc.M008717200","article-title":"IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by vaccinia virus E3L protein","volume":"23","author":"Smith","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0965","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","article-title":"Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity","volume":"94","author":"Smith","year":"2013","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0970","doi-asserted-by":"crossref","first-page":"11950","DOI":"10.1128\/JVI.01672-13","article-title":"Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies","volume":"87","author":"Song","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0975","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.virol.2008.02.018","article-title":"The highly conserved orthopoxvirus 68k ankyrin-like protein is part of a cellular SCF ubiquitin ligase complex","volume":"374","author":"Sperling","year":"2008","journal-title":"Virology"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0980","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1128\/JVI.01628-08","article-title":"The orthopoxvirus 68-kiloDalton ankyrin-like protein is essential for DNA replication and complete gene expression of modified vaccinia virus Ankara in nonpermissive human and murine cells","volume":"83","author":"Sperling","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb0985","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0092-8674(92)90273-F","article-title":"Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein","volume":"71","author":"Spriggs","year":"1992","journal-title":"Cell"},{"key":"10.1016\/bs.aivir.2016.07.001_bb0995","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2144\/00286st04","article-title":"Transient host range selection for genetic engineering of modified vaccinia virus Ankara","volume":"28","author":"Staib","year":"2000","journal-title":"Biotechniques"},{"key":"10.1016\/bs.aivir.2016.07.001_bb9020","first-page":"77","article-title":"Construction and isolation of recombinant MVA vaccinia virus and poxvirology","volume":"269","author":"Staib","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1000","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1099\/vir.0.80646-0","article-title":"Inactivation of the viral interleukin 1\u03b2 receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara","volume":"86","author":"Staib","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1005","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1099\/vir.0.82068-0","article-title":"Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara","volume":"87","author":"Staib","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1010","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebola Virus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/v4020280","article-title":"Henipavirus mediated membrane fusion, virus entry and targeted therapeutics","volume":"4","author":"Steffen","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1020","first-page":"1149","article-title":"Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (\u201cMVA virus\u201d)","volume":"27","author":"Stickl","year":"1971","journal-title":"Munch Med. Wochenschr."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1025","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"MVA-Stufenimpfung gegen Pocken","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch. Med. Wochenschr."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1030","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with Monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1035","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1073\/pnas.0307140101","article-title":"Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association","volume":"101","author":"Sui","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrmicro2950","article-title":"West Nile virus infection and immunity","volume":"11","author":"Suthar","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1045","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1050","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-5793(95)00843-X","article-title":"Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase","volume":"371","author":"Sutter","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1060","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1099\/0022-1317-83-11-2833","article-title":"The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model","volume":"83","author":"Symons","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1065","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/aid.1992.8.1445","article-title":"Highly attenuated poxvirus vectors","volume":"8","author":"Tartaglia","year":"1992","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1080","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.virol.2005.09.032","article-title":"Near death experiences: poxvirus regulation of apoptotic death","volume":"344","author":"Taylor","year":"2006","journal-title":"Virology"},{"issue":"7","key":"10.1016\/bs.aivir.2016.07.001_bb1085","first-page":"1795","article-title":"Repeated high-dose (5 \u00d7 108TCID50) toxicity study, of a third generation smallpox vaccine (IMVAMUNE), in New Zealand white rabbits","volume":"12","author":"Tree","year":"2016","journal-title":"Hum. Vac. Immunother."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1090","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1016\/j.vaccine.2015.08.032","article-title":"Sex difference in immune response to vaccination: a participant-level meta-analysis of randomized trials of IMVAMUNE\u00ae smallpox vaccine","volume":"33","author":"Troy","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.clim.2014.09.005","article-title":"Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques","volume":"155","author":"Valentin","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/aid.2011.0234","article-title":"The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies","volume":"28","author":"Van Rompay","year":"2012","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1105","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.vaccine.2008.01.016","article-title":"Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions","volume":"26","author":"Veits","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1110","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1128\/JVI.00945-14","article-title":"Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara","volume":"88","author":"Volz","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1115","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1128\/JVI.00614-15","article-title":"Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein","volume":"89","author":"Volz","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1120","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.vaccine.2016.02.042","article-title":"Immunogenicity and protective efficacy of recombinant modified vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens","volume":"34","author":"Volz","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1125","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1016\/j.vaccine.2014.08.022","article-title":"Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis","volume":"32","author":"von Sonnenburg","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1130","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa1407647","article-title":"Human infection with a zoonotic orthopoxvirus in the country of Georgia","volume":"372","author":"Vora","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4049\/jimmunol.174.1.449","article-title":"Differential immunogenicity of various heterologous prime-boost vaccine regimens using dan and viral vectors in healthy volunteers","volume":"174","author":"Vuola","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1140","doi-asserted-by":"crossref","first-page":"e24832","DOI":"10.1371\/journal.pone.0024832","article-title":"Progression of pathogenic events in cynomolgus macaques infected with Variola virus","volume":"6","author":"Wahl-Jensen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1145","doi-asserted-by":"crossref","first-page":"12102","DOI":"10.1128\/JVI.01190-07","article-title":"Modified vaccinia virus Ankara induces toll-like receptor-independent type I interferon responses","volume":"81","author":"Waibler","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1150","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/JVI.01617-08","article-title":"Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components","volume":"83","author":"Waibler","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1155","doi-asserted-by":"crossref","first-page":"14345","DOI":"10.1073\/pnas.2235583100","article-title":"Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis","volume":"100","author":"Wasilenko","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1160","doi-asserted-by":"crossref","first-page":"14031","DOI":"10.1128\/JVI.79.22.14031-14043.2005","article-title":"The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation","volume":"79","author":"Wasilenko","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1165","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"Webster","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1170","doi-asserted-by":"crossref","first-page":"e73511","DOI":"10.1371\/journal.pone.0073511","article-title":"A novel naturally occurring tandem promoter in modified vaccinia virus Ankara drives very early gene expression and potent immune responses","volume":"8","author":"Wennier","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1175","series-title":"Advances in Virus Research","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-3527(08)00003-1","article-title":"Chapter 3 poxvirus host range genes","author":"Werden","year":"2008"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1180","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1128\/IAI.73.6.3814-3816.2005","article-title":"Boosting with Poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs","volume":"73","author":"Williams","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tube.2004.11.001","article-title":"An assay to compare the infectivity of mycobacterium tuberculosis isolates based on aerosol infection of guinea pigs and assessment of bacteriology","volume":"85","author":"Williams","year":"2005","journal-title":"Tuberculosis"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0092-8674(80)90135-X","article-title":"Tandem repeats within the inverted terminal repetition of vaccinia virus DNA","volume":"21","author":"Wittek","year":"1980","journal-title":"Cell"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1195","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0092-8674(80)90485-7","article-title":"Expression of the vaccinia virus genome: analysis and mapping of mRNAs encoded within the inverted terminal repetition","volume":"21","author":"Wittek","year":"1980","journal-title":"Cell"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1200","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0264-410X(96)00072-2","article-title":"Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model","volume":"14","author":"Wyatt","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/bs.aivir.2016.07.001_bb1205","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1210","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1128\/JVI.00687-09","article-title":"Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection","volume":"83","author":"Wyatt","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1215","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1128\/JVI.76.10.5251-5259.2002","article-title":"Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus","volume":"76","author":"Xiang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1220","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMc1502983","article-title":"Human infection with a novel avian influenza A(H5N6) virus","volume":"373","author":"Yang","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1225","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1128\/JVI.00339-15","article-title":"Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system","volume":"89","author":"Yuan","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1230","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1073\/pnas.1323279111","article-title":"Rapid generation of a mouse model for Middle East respiratory syndrome","volume":"111","author":"Zhao","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1743-422X-10-34","article-title":"Interleukin-1\u03b2 receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1\u03b2 activity produced in various virus-infected antigen-presenting cells","volume":"10","author":"Zimmerling","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/bs.aivir.2016.07.001_bb1240","doi-asserted-by":"crossref","first-page":"e0122653","DOI":"10.1371\/journal.pone.0122653","article-title":"Cardiac safety of modified vaccinia Ankara for vaccination against smallpox in a young, healthy study population","volume":"10","author":"Zitzmann-Roth","year":"2015","journal-title":"PLoS One"}],"container-title":["Advances in Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065352716300380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065352716300380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:17:38Z","timestamp":1718716658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065352716300380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780128118016"],"references-count":251,"URL":"https:\/\/doi.org\/10.1016\/bs.aivir.2016.07.001","relation":{},"ISSN":["0065-3527"],"issn-type":[{"value":"0065-3527","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}